Helping You to Find Mechanistic Keys to Biomarker Discovery for Precision Oncology
View video
Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors
January 21, 2021: A new article on HER2-targeted tyrosine kinase inhibitors is [...]
Predictive approach for clinical response to chemotherapy
December 21: A new article on malignant ascites as a model for [...]
PREMIUM BENEFITS OF NTRC PRECISION ONCOLOGY: Cell-Based Assays, Drug Combinations, High-Throughput Screening
Integration of cancer biology and big data analysis
Identification of patient selection markers
Side-by-side comparison with known anti-cancer agents
Discovery of targeted and novel synergistic drug combinations
Science-driven technology platforms
Short turnaround times
